Current guidelines for adult GH replacement

Reviews in Endocrine and Metabolic Disorders

Volumn 6, Issue 1, 2005, Pages 63-70

  Doga, Mauro ^a   Bonadonna, Stefania ^b   Gola, Monica ^a   Solerte, Sebastiano Bruno ^c   Amato, Giovanni ^d   Carella, Carlo ^d   Giustina, Andrea ^b  

^a CARLO POMA HOSPITAL   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; HUMAN GROWTH HORMONE; SOMATOMEDIN C;

ADULT; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FLUID RETENTION; FOLLOW UP; GLUCOSE METABOLISM; GROWTH HORMONE DEFICIENCY; HEALTH PROGRAM; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS DISEASE; HYPOPITUITARISM; OSTEOLYSIS; OSTEOPOROSIS; PRACTICE GUIDELINE; PREGNANCY; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

ADULT; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; PRACTICE GUIDELINES;

EID: 17644398174     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11154-005-5226-y     Document Type: Review

References (41)

1. Jorgensen JOL, Thuensen I, Ingemannhansen T, Pedersen S, Jorgensen J, Shakkebaek NE, Christiansen JS. Beneficial effects of growth hormone treatment in GH deficient adults. Lancet 1989;1:1221-1225.
2. Solomon F, Cuneo RC, Heso R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adultswith growth hormone deficiency. N Eng J Med 1989;321:309-317.
3. Bengtsson B, Eden S, Lonn L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L, Isaksson O. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 1993,;76:309-317.
4. Carrol PV, Christ ER, Bengtsson BA, Carlsson I, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998;83:382-395.
5. GHR Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-381.
6. Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285-288.
7. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM. Association between premature mortality and hypopituitarism. West Midlans Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
8. Besson A, Salemi S, Gallati S, Jenal A, Horn R, Mullis PS, Mullis PE. Reduced longevity in untreated patients with isolated growth hormone deficiency. J Clin Endocrinol Metab 2003;88:3664-3667.
9. Jorgensen JO, Flyvbierg A, Dinesen J, Lund H, Alberti KG, Orskov H, Christiansen JS. Serum profiles and short-term metabolic effects of pituitary and authentic biosynthetic human growth hormone in man. A double-blind cross-over study. Acta Endocrinol (Copenh) 1987;116:381-386.
10. Jorgensen JO, Flyvbierg A, Laurotzen T, Orskov H, Christiansen JS. Sub-cutaneous degradation of byosinthetic human growth hormone in growth hormone deficient patients. Acta Endocrinol (Copenh) 1988;118:154-158.
11. Giustina A, Veldhuis JD. Pathophisiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 1998;19:717-797.
12. Drake WM, Howell SJ, Manson JP, Shalet SM. Optimizing GH therapy in adults and children. Endocr Rev 2001;22:425-450.
13. Amato G, Carella C, Fazio S, La Montagna G, Cittadini A, Sabatin Marciano-Mone C, Sacca L, Bellastella A. Body composition, bone metabolism, and heart structure an function in growth hormonne (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993;77:1671-1676.
14. Rose S. Evidence base for GH treatment. Highlights 2003;11:4-10.
15. Rosen T, Bosaeus I, Tolli J, Lindstedt G, Bengtsson BA. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf) 1993;38:63-71.
16. Whitehead HM, Boreham C, McIlrath EM, Sheridan B, Kennedy I, Atkinson AB, Hadden DR. Growth hormone treatment of adults with growth hormone deficiency: Results of a 13-month placebo controlled cross-over study. Clin Endocrinol (Oxf) 1992;36:45-52.
17. Giustina A, Bussi AR, Jacobello C, WehrenbergWB. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995;80:122-129.
18. Barman P, Broman JE, Hetta J, Wiklund I, Erfurth EM, Hagg E, Karlsson FA. Quality of life in adults with growth hormone (GH) deficiency: Response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab 1995;80:3585-3590.
19. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L, Wiren L. The QoL-AGHDA: An instrument for the assessment of quality of life in adults with growth hormone deficiency. Qual Life Res 1999;8:373-383.
20. Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol 1997;137:240-245.
21. Colao A, Di Somma C, Piovanello R, Loche S, Aimaretti G, Cerbone G, Faggiano A, Cornelli G, Ghigo E, Lombardi G. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endoctinol Metab 1999;84:1919-1924.
22. Manelli A, Carpinteri R, Bossoni S, Burattin A, Bonadonna S, Agabiti Rosei E, Giustina A. Growth hormone in glucocorticoid-induced osteoporosis. Front Horm Res 2002;30:174-183.
23. Vandeweghe M, Taelman P, Kaufman JM. Short and long term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol (Oxf) 1993;39:409-415.
24. Baum HB, Biller BM, Finkelstein JS, Cannistraro KB, Oppenhein DS, Schoenfeld DA, Michel TH, Wittink H, Klibanski A. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med 1996;125:883-890.
25. Biller Bm, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A. Withdrawal of long term physiological growth hormone (GH) administration: Differential effects on bone density and body composition in men with adult-onset Gh deficiency. J Clin Endocrinol Metab 2000;85:970-976.
26. Johansson AG, Engstrom BE, Ljungall S, Karlsson FA, Burman P. Gender differences in the effects of long term growth hormone (GH) treatment on bone in adults with GH deficiency. J Clin Endocrinol Metab 1999;84:2002-2007.
27. Volterrani M, Desenzani P, Lorusso R, d'Aloia A, Manelli F, Giustina A. Haemodinamic effects of intravenous growth hormone in congestive heart failure. Lancet 1997;349:1067-1068.
28. Giustina A, Lorusso R, Borghetti V, Bulgari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am Heart J 1996;131:620-622. AMJ Cardiol 95.
29. Giustina A, Lorusso R, Borghetti V, Bulgari G, Misitano V, Alfieri O. Impaired spontaneous growth hormone secretion in severe dialated cardiomyopathy. Am Heart J 1996;131:620-622. AMJ Cardiol 95.
30. Clayton P, Cowell C. Safety issues in children and adolescents during growth hormone therapy. Growth Horm IGF Res 2000;10:306-317.
31. Binnerts A, Swart GR, Wilson JHP, Hoogerbrugge N, Pols AHP, Birkenhager JC, Lamberts SWJ. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clin Endocrinol 1992;37:79-87.
32. Giustina A, Romanelli G, Candrina R, Giustina G. Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J Clin Endocrinol Metab 1989;68:120-124.
33. Johannsson G, Jorgensen J. Safety aspects of GH replacement in adults. Growth Horm IGF Res 2000;11:2.
34. Swerdlow A. design and interpretation of studies of risk of ancer and other long-term morbidity and mortality after GH treatment. Growth Horm IGF Res 2000;10:318-323.
35. Cohen P, Clemmons D, Rosenfeld R. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000;10:297-305.
36. Dattani M, Preece M. Growth hormone deficiency and related disorders: Insights in causation, diagnosis, and treatment. Lancet 2004;12:1977-1987.
37. De Boer H, Blek CJ. Monitoring of growth hormone replacement therapy in adults, based on measurement of serum markers. J Clin Endocrinol Metab 1996;81:1371-1377.
38. Amato G, Mazziotti G, Di Somma C, Lalli E, De Felice G, Conte M, Rotondi M, Pietrosante M, Lombardi G, Bellastella A, Carella C, Colao A. Recombinant growth hormone (GH) therapy in GH-deficient adults:a long-term controlled study on daily versus thrice week injections. J Clin Endocrinol Metab 2000;10:3720-3725.
39. Thoren M, Hilding A, Baxter RC, Degerblad M, Wival-Helleryd Il, Hall K. Serum insulin growth factor 1 (IGF-1), IGF-binding protein-1 and -3, and the acid labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1997;82:223-228.
40. Yamamoto H, Sohmiya M, Oka N, Katio Y. Effects of aging and sex on plasma insulin-like growth factor-1 (IGF-1) levels in normal adults. Acta Endocrinol 1991;124:497-500.
41. de Boer H, van der Veen E. Guidelines for optimizing growth hormone replacement therapy in adults. Horm Res 1997;48:21-30.